|1.||D'Incalci, Maurizio: 30 articles (03/2015 - 01/2002)|
|2.||D'Incalci, M: 17 articles (12/2015 - 05/2000)|
|3.||Blay, Jean-Yves: 17 articles (07/2015 - 11/2005)|
|4.||Le Cesne, Axel: 14 articles (07/2015 - 07/2007)|
|5.||Jimeno, J: 14 articles (05/2011 - 05/2000)|
|6.||Nieto, Antonio: 13 articles (09/2015 - 05/2010)|
|7.||Sanfilippo, Roberta: 11 articles (07/2015 - 07/2007)|
|8.||Ray-Coquard, Isabelle: 11 articles (04/2015 - 10/2008)|
|9.||Jimeno, Jose: 11 articles (08/2011 - 01/2002)|
|10.||Alfaro, Vicente: 10 articles (09/2015 - 05/2007)|
|1.||Sarcoma (Soft Tissue Sarcoma)
06/01/2012 - "Previous studies in sarcoma found that a composite gene signature, including high expression of nucleotide excision repair (NER) genes (XPG and/or ERCC1) and low expression of homologous recombination repair (HR) genes (BRCA1), identifies a highly sensitive population of patients with significantly improved outcome to trabectedin. "
01/01/2013 - "The present paper on a promising treatment with neoadjuvant trabectedin of patients with high-grade pleomorphic sarcoma might suggest that such treatment approach may provide a greater chance of cure and survival of such patients."
01/01/2013 - "This polymorphism was previously shown to be associated with better outcome in soft tissue sarcoma patients treated with trabectedin. "
08/01/2014 - "Trabectedin may be especially effective against translocation-related sarcomas."
01/01/2012 - "Trabectedin, a new antitumor compound originally derived from a marine tunicate, is clinically effective in soft tissue sarcoma. "
|2.||Ovarian Neoplasms (Ovarian Cancer)
01/01/2007 - "The introduction of trabectedin expands the currently limited range of effective treatment options for patients with advanced or metastatic STS; trabectedin also has the potential to be a beneficial treatment for advanced or recurrent ovarian cancer."
01/01/2015 - "This study provides the evidence that α-PD-1 mAb can produce a synergistic antitumor efficacy when combined with Trabectedin, a clinically available anticancer agent, supporting a direct translation of this combination strategy in clinic for the treatment of ovarian cancer."
01/01/2015 - "In this study, we investigated whether Trabectedin (ET-743), a novel anticancer agent currently used for treating relapsed ovarian cancer, can synergize with anti (α)-PD-1 mAb to increase antitumor activity in the murine ID8 ovarian cancer model. "
12/01/2014 - "The current safety and tolerability profile of trabectedin, based on the evaluation in clinical trials of patients treated with the recommended treatment regimens for STS and recurrent ovarian cancer, was reviewed. "
03/01/2013 - "Three phase II studies evaluated trabectedin monotherapy as second-/third-line therapy in patients with refractory/recurrent ovarian cancer (ROC). "
12/01/2011 - "The aim of this retrospective analysis was to look at the efficacy of trabectedin in the subgroup of uterine leiomyosarcoma. "
01/01/2012 - "A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: a gynecologic oncology group study."
04/01/2015 - "Trabectedin has shown activity in pretreated leiomyosarcoma. "
01/01/2015 - "Long-lasting activity of trabectedin in refractory uterine leiomyosarcoma: a case report."
01/01/2015 - "Management Strategies in Advanced Uterine Leiomyosarcoma: Focus on Trabectedin."
07/01/2014 - "The extraction recovery was >81% and the lower limit of quantification 0.025 ng/ml. The method was successfully applied to study trabectedin pharmacokinetics in a patient with a liposarcoma who received 1.3 mg/m² as a 24 h continuous i.v. infusion."
01/01/2015 - "Myxoid (round cell) liposarcomas appear to be sensitive to trabectedin, which is currently under U.S. "
03/15/2010 - "In conclusion, trabectedin has dual effects in liposarcoma: in addition to direct growth inhibition, it affects the tumor microenvironment by reducing the production of key inflammatory mediators."
06/01/2008 - "In myxoid and round-cell liposarcomas trabectedin seems exceptionally active. "
03/01/2012 - "To evaluate neoadjuvant trabectedin (1.5 mg/m(2) 24-h i.v. infusion every 3 weeks; three to six cycles) in patients with locally advanced myoxid liposarcoma (ML) previously untreated with chemotherapy or radiation. "
02/01/2001 - "A Phase II trial to assess the efficacy of ET-743 against this highly refractory neoplasm has been initiated on the basis of this observation. "
07/01/2015 - "Emerging clinical studies will evaluate novel medical treatment approaches including the tetra-hydroisoquinoline alkaloid trabectedin (European Organisation for Research and Treatment of Cancer (EORTC) phase II trial 1320) and SMO or AKT inhibitors in molecularly selected cases."
12/01/2013 - "Furthermore, in-vitro studies and single patient experience indicate that trabectedin may be an effective therapy in this tumor type. "
06/01/2013 - "Indeed, the unusual pattern of tumor response to trabectedin has raised queries about the appropriateness of conventional radiological evaluation of efficacy according to Response Evaluation Criteria in Solid Tumors and has prompted the search for new end points for Phase II studies. "
11/01/2012 - "A phase I trial and pharmacokinetic study of a 24-hour infusion of trabectedin (Yondelis®, ET-743) in children and adolescents with relapsed or refractory solid tumors."
|2.||trabectedin (ecteinascidin 743)
|3.||pegylated liposomal doxorubicin
|10.||DNA (Deoxyribonucleic Acid)
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)